酵素促伤口清创市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

在预测期内，酵素促伤口清创市场预计将以约 5.3% 的复合年增长率增长。

推动市场增长的关键因素是糖尿病、癌症和其他自身免疫性疾病等慢性病发病率的增加，这是推动增长的主要因素之一。

根据国际糖尿病联合会的数据，2019 年约有 4.63 亿成年人患有糖尿病，到 2045 年将增加到 7 亿，其中约 3.74 亿患有 2 型糖尿病。患糖尿病的风险增加 糖尿病患者的增加表明慢性伤口（例如糖尿病足溃疡）的数量增加，这促进了所研究市场的增长。 此外，政府增加研发项目投资以开发该部分的医疗保健基础设施正在推动市场增长。 然而，严格的监管政策是市场增长的主要障碍。

酵素促伤口清创的市场趋势

基于胶原酵素的酵素促伤口清创有望实现快速增长

基于胶原酵素的酵素促伤口清创术主要用于手术伤口癒合。 由于癌症手术后的疤痕较大且较深，会产生渗出液，需要定期处理。 因此，正确使用这些产品可以帮助治疗大伤口，并大大降低感染风险。 因此，预计慢性病的增加将增加对酵素促伤口清创的需求，从而推动预测期内的市场增长。

此外，预计全球交通事故、烧伤和受伤等事故的增加也将推动增长。 据世界卫生组织统计，每年有 135 万人死于交通事故。 因此，预计事故数量的增加将推动该行业的增长。

北美主导市场，预计在预测期内保持不变

在预测期内，预计北美将主导整个市场。 这一市场增长是由于主要参与者的存在、该地区慢性病和事故的高发率、完善的医疗基础设施等因素造成的。 根据美国创伤外科医师协会的数据，2017 年全球约有 120 万人死亡，每年约有 3,242 人死于道路交通事故。 此外，有益的政府举措和不断增加的研究伙伴关係是推动市场增长的一些因素。

酵素促伤口清创市场竞争分析

酵素促伤口清创市场竞争适中，由几家大型企业组成。 目前上市的公司包括 B. Braun Melsungen AG、ConvaTec Inc.、Smith & Nephew、Integra LifeSciences Corporation、Molnlycke Health Care AB、Healthpoint, Ltd 和 MediWound。

其他好处

• Excel 格式的市场预测 (ME) 表
• 三个月的分析师支持

内容

第一章介绍

• 调查结果
• 调查假设
• 本次调查的范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

• 市场概览
• 市场驱动因素
  • 慢性伤口的发生率增加
  • 事故数量增加
  • 增加技术先进的产品
• 市场製约因素
  • 严格的监管政策
• 波特的五力分析
  • 新进入者的威胁
  • 买方/消费者议价能力
  • 供应商的议价能力
  • 替代品的威胁
  • 竞争公司之间的敌对关係

第 5 章市场细分

• 按类型
  • 慢性伤口
  • 急性伤口
• 按产品分类
  • 胶原酵素产品
  • 木瓜蛋白酵素产品
  • 其他
• 最终用户
  • 医院
  • 家庭护理
  • 其他
• 按地区
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 中东和非洲
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲地区
  • 南美洲地区
    • 巴西
    • 阿根廷
    • 其他南美洲

第六章竞争格局

• 公司简介
  • B. Braun Melsungen AG
  • ConvaTec Inc.
  • Smith & Nephew
  • Integra LifeSciences Corporation
  • Molnlycke Health Care AB
  • Healthpoint, Ltd
  • MediWound

第7章 市场机会今后动向

The Enzymatic Wound Debridement market is projected to grow with a CAGR of nearly 5.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases is one of the major factors boosting growth.

According to International Diabetes Federation, roughly 463 million adults were living with diabetes in the year 2019, by 2045 this will rise to 700 million and around 374 million people are at increased risk of developing type 2 diabetes. The rising cases of diabetic people indicate the rising number of chronic wounds such as Diabetic Foot Ulcers, etc. which is augmenting the growth of the market studied. Furthermore, the growing investments in research and development programs by the government to develop the medical infrastructure in this section is boosting the market growth. However, the stringent regulatory policies is the major drawback of the market growth.

Enzymatic Wound Debridement Market Trends

Collagenase-based Enzymatic Wound Debridement Products are Expected to Witness Rapid Growth

Collagenase-based enzymatic wound debridement products are predominantly used for healing surgical wounds. Most surgical wounds after cancer surgery are relatively large and deep, which generates exudate that needs regular supervision. Thus, the proper use of these products helps handle large wounds, which substantially reduce the risk of infection. Therefore, the rising incidence of chronic diseases is anticipated to increase the demand for enzymatic wound debridement products, thereby propelling market growth over the forecast period.

Furthermore, an increasing number of accidents, such as road accidents, burns, and trauma, across the world is also projected to propel growth. According to World Health Organization, 1.35 million people die every year as a result of road traffic crashes. Thus, rise in the number of accidents is expected to boost the growth of the segment.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, high prevalence of chronic diseases and accidents in the region, and established healthcare infrastructure. According to the American Association for the Surgery of Trauma, in 2017, around 1.2 million people died globally, accounting for deaths of around 3,242 people per day in road accidents every year. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Enzymatic Wound Debridement Market Competitive Analysis

The Enzymatic Wound Debridement market is moderately competitive and consists of several major players. Some of the companies which are currently present in the market are B. Braun Melsungen AG, ConvaTec Inc., Smith & Nephew, Integra LifeSciences Corporation, Molnlycke Health Care AB, Healthpoint, Ltd, MediWound.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Incidence of Chronic Wounds
  • 4.2.2 Increasing Number of Accidents
  • 4.2.3 Increasing Technologically Advanced Products
• 4.3 Market Restraints
  • 4.3.1 Stringent regulatory policies
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Type
  • 5.1.1 Chronic Wounds
  • 5.1.2 Acute Wounds
• 5.2 By Product
  • 5.2.1 Collagenase Product
  • 5.2.2 Papain Product
  • 5.2.3 Others
• 5.3 By End-User
  • 5.3.1 Hospitals
  • 5.3.2 Homecare
  • 5.3.3 Others
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 B. Braun Melsungen AG
  • 6.1.2 ConvaTec Inc.
  • 6.1.3 Smith & Nephew
  • 6.1.4 Integra LifeSciences Corporation
  • 6.1.5 Molnlycke Health Care AB
  • 6.1.6 Healthpoint, Ltd
  • 6.1.7 MediWound

7 MARKET OPPORTUNITIES AND FUTURE TRENDS